75 related articles for article (PubMed ID: 21507170)
1. Voriconazole toxicity related to polymorphisms in CYP2C19.
Suan D; O'Connor K; Booth DR; Liddle C; Stewart GJ
Intern Med J; 2011 Apr; 41(4):364-5. PubMed ID: 21507170
[No Abstract] [Full Text] [Related]
2. Voriconazole therapeutic drug monitoring: focus on safety.
Pasqualotto AC; Xavier MO; Andreolla HF; Linden R
Expert Opin Drug Saf; 2010 Jan; 9(1):125-37. PubMed ID: 20021293
[TBL] [Abstract][Full Text] [Related]
3. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes.
Matsumoto K; Ikawa K; Abematsu K; Fukunaga N; Nishida K; Fukamizu T; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
Int J Antimicrob Agents; 2009 Jul; 34(1):91-4. PubMed ID: 19261446
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics of the triazole antifungal agent voriconazole.
Mikus G; Scholz IM; Weiss J
Pharmacogenomics; 2011 Jun; 12(6):861-72. PubMed ID: 21692616
[TBL] [Abstract][Full Text] [Related]
5. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.
Hassan A; Burhenne J; Riedel KD; Weiss J; Mikus G; Haefeli WE; Czock D
Ther Drug Monit; 2011 Feb; 33(1):86-93. PubMed ID: 21192313
[TBL] [Abstract][Full Text] [Related]
6. A case-report of unpredictable and massive voriconazole intoxication in a patient with extensive CYP2C19 and CYP2C9 polymorphisms.
Lemaitre F; Barbaz M; Scailteux LM; Uhel F; Tadié JM; Verdier MC; Bellissant E
Drug Metab Pharmacokinet; 2013; 28(5):439-41. PubMed ID: 23545593
[TBL] [Abstract][Full Text] [Related]
7. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype.
Zonios D; Yamazaki H; Murayama N; Natarajan V; Palmore T; Childs R; Skinner J; Bennett JE
J Infect Dis; 2014 Jun; 209(12):1941-8. PubMed ID: 24403552
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics and beyond: variability of voriconazole plasma levels in a patient with primary immunodeficiency.
Autmizguine J; Krajinovic M; Rousseau J; Théorêt Y; Litalien C; Marquis C; Tapiéro B; Ovetchkine P
Pharmacogenomics; 2012 Dec; 13(16):1961-5. PubMed ID: 23215888
[TBL] [Abstract][Full Text] [Related]
9. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.
Weiss J; Ten Hoevel MM; Burhenne J; Walter-Sack I; Hoffmann MM; Rengelshausen J; Haefeli WE; Mikus G
J Clin Pharmacol; 2009 Feb; 49(2):196-204. PubMed ID: 19033450
[TBL] [Abstract][Full Text] [Related]
10. Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.
Moriyama B; Falade-Nwulia O; Leung J; Penzak SR; JJingo C; Huang X; Henning SA; Wilson WH; Walsh TJ
Mycoses; 2011 Nov; 54(6):e877-9. PubMed ID: 21615537
[TBL] [Abstract][Full Text] [Related]
11. Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children.
Narita A; Muramatsu H; Sakaguchi H; Doisaki S; Tanaka M; Hama A; Shimada A; Takahashi Y; Yoshida N; Matsumoto K; Kato K; Kudo K; Furukawa-Hibi Y; Yamada K; Kojima S
J Pediatr Hematol Oncol; 2013 Jul; 35(5):e219-23. PubMed ID: 23588332
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status.
Ikeda Y; Umemura K; Kondo K; Sekiguchi K; Miyoshi S; Nakashima M
Clin Pharmacol Ther; 2004 Jun; 75(6):587-8. PubMed ID: 15179414
[No Abstract] [Full Text] [Related]
13. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Trégouet DA; Amrein C; Boussaud V; Chevalier P; Lillo-Lelouet A; Le Beller C; Laurent-Puig P; Beaune PH; Billaud EM; Loriot MA
Eur J Clin Pharmacol; 2011 Mar; 67(3):253-60. PubMed ID: 21038076
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
[TBL] [Abstract][Full Text] [Related]
15. [Clinical implication of therapeutic drug monitoring on voriconazole from the aspect of the analysis for CYP2C19 gene].
Kimura M; Yamagishi Y; Kawasumi N; Hagihara M; Hasegawa T; Mikamo H
Jpn J Antibiot; 2010 Jun; 63(3):255-64. PubMed ID: 20976881
[TBL] [Abstract][Full Text] [Related]
16. Clinical importance of the CYP2C19*17 variant allele for voriconazole.
Dolton MJ; McLachlan AJ
Br J Clin Pharmacol; 2011 Jan; 71(1):137-8. PubMed ID: 21143511
[No Abstract] [Full Text] [Related]
17. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
[TBL] [Abstract][Full Text] [Related]
18. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial.
Park WB; Kim NH; Kim KH; Lee SH; Nam WS; Yoon SH; Song KH; Choe PG; Kim NJ; Jang IJ; Oh MD; Yu KS
Clin Infect Dis; 2012 Oct; 55(8):1080-7. PubMed ID: 22761409
[TBL] [Abstract][Full Text] [Related]
19. [Complex visual hallucinations induced by voriconazole].
Fernández-Ruiz M; López-Medrano F; Gutiérrez E; Aguado JM
Med Clin (Barc); 2009 Jun; 133(4):156-7. PubMed ID: 19540418
[No Abstract] [Full Text] [Related]
20. Hallucinations during voriconazole therapy.
Zonios DI; Gea-Banacloche J; Childs R; Bennett JE
Clin Infect Dis; 2008 Jul; 47(1):e7-e10. PubMed ID: 18491963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
